Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Chris Schott | JPMorgan | 12 questions · 0% challenging |
| Terence Flynn | Morgan Stanley | 9 questions · 22% challenging |
| Steve Scala | TD Cowen | 9 questions · 33% challenging |
| Umer Raffat | Evercore ISI | 8 questions · 25% challenging |
| Vamil Divan | Guggenheim | 8 questions · 25% challenging |
| Courtney Breen | Bernstein | 7 questions · 0% challenging |
| Dave Risinger | Leerink Partners | 7 questions · 14% challenging |
| Evan Seigerman | BMO Capital Markets | 7 questions · 0% challenging |
| Asad Haider | Goldman Sachs | 7 questions · 29% challenging |
| Geoff Meacham | Citigroup | 7 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| JPMorgan | 1 analyst | 12 questions · 0% challenging |
| TD Cowen | 1 analyst | 9 questions · 33% challenging |
| Goldman Sachs | 2 analysts | 9 questions · 22% challenging |
| Morgan Stanley | 1 analyst | 9 questions · 22% challenging |
| Evercore ISI | 1 analyst | 8 questions · 25% challenging |
| Guggenheim | 1 analyst | 8 questions · 25% challenging |
| Citigroup | 1 analyst | 7 questions · 0% challenging |
| Bernstein | 1 analyst | 7 questions · 0% challenging |
No 8-K events recorded for this window.
Pfizer delivered Q1 revenues of $14.5 billion, exceeding expectations with 2% operational growth, and adjusted EPS of $0.75. Excluding COVID products, the underlying business delivered approximately 7% operational growth. The Vyndamax patent settlement extended exclusivity, and oncology pipeline readouts were positive. R&D investment increased 11% to support the pipeline. Full-year 2026 guidance was reaffirmed at $59.5-62.5 billion revenue and $2.80-$3.00 adjusted EPS. LOE headwinds through 2028 preceded a growth inflection.
Innovation & R&D | M&A | Regulation Policy | Competitive Dynamics | Demand | Capital Allocation | Trade Tariffs | Product Launch | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 10 | 4 | 3 | 5 | 6 | 3 | 6 | |
| 2025Q1 | 4 | 3 | 4 | 1 | 2 | 3 | 9 | 1 |
| 2025Q2 | 5 | 5 | 9 | 3 | 2 | 1 | 4 | 1 |
| 2025Q3 | 5 | 8 | 6 | 3 | 4 | 3 | 1 | 2 |
| 2025Q4 | 15 | 3 | 6 | 1 | 1 | |||
| 2026Q1 | 3 | 2 | 2 | 1 | 4 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Innovation & R&D | 10 | 4 | 5 | 5 | 15 | 3 |
| M&A | 4 | 3 | 5 | 8 | 3 | 2 |
| Regulation Policy | 3 | 4 | 9 | 6 | ||
| Competitive Dynamics | 5 | 1 | 3 | 3 | 6 | 2 |
| Demand | 6 | 2 | 2 | 4 | 1 | |
| Capital Allocation | 3 | 3 | 1 | 3 | 1 | 4 |
| Trade Tariffs | 9 | 4 | 1 | |||
| Product Launch | 6 | 1 | 1 | 2 | 1 | 1 |
Calendar quarter Q1 2026Earnings call May 5, 2026
FY2026 Q1 in brief
Pfizer delivered Q1 revenues of $14.5 billion, exceeding expectations with 2% operational growth, and adjusted EPS of $0.75.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for Pfizer (PFE), FY2026 Q1: 5/10. Scores: Pfizer’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: PFE daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Net margin | FCF |
|---|---|---|---|---|---|---|
| FY2024 Q4 | $17.76B | +21.9% | $0.07 | +112.1% | 2.3% | $5.80B |
| FY2025 Q1 | $13.71B | -7.8% | $0.52 | -5.1% | 21.6% | $1.77B |
| FY2025 Q2 | $14.65B | +10.3% | $0.51 | — | 19.9% | $-1.20B |
| FY2025 Q3 | $16.65B | -5.9% | $0.62 | -20.9% | 21.3% | $4.00B |
| FY2025 Q4 | $17.56B | -1.2% | $-0.29 | -503.3% | -9.4% | $4.50B |
| FY2026 Q1Selected | $14.45B | +5.4% | $0.47 | -9.5% | 18.6% | $2.18B |
| FY2026 Q2 | $15.03B | +2.6% | $-0.04 | -108.5% | -1.6% | $302M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
GAAP revenue YoY +5.37% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
What PFE and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“the recently announced Pfizer settlement for Vyndamax impacts how you think about the TTR cardiomyopathy landscape”
An analyst asks about Pfizer's Vyndamax settlement (affecting stabilizer-class generic timing); Alnylam says its growth outlook is not dependent on stabilizer generic entry.
“Pfizer and IQVIA Holdings Inc. entered into a strategic regional promotion agreement covering selected Pfizer products across 23 countries in Europe.”
Pfizer signed a strategic regional promotion agreement with IQVIA covering selected products across 23 European countries, a commercial-services win that expands IQVIA's partnership with Pfizer.
“including both internally discovered programs and opportunities we have added through strategic moves such as our acquisition of Metsera and our in-licensing agreements with 3SBio and YaoPharma.”
Pfizer added pipeline assets via an in-licensing agreement with YaoPharma.
“including both internally discovered programs and opportunities we have added through strategic moves such as our acquisition of Metsera and our in-licensing agreements with 3SBio and YaoPharma.”
Pfizer added pipeline assets via an in-licensing agreement with 3SBio.
“We closed on the sale of our stake in ViiV in the second quarter, providing us with approximately $1.65 billion in net proceeds, after taxes and customary closing costs.”
Pfizer divested its minority stake in ViiV Healthcare for roughly $1.65 billion net, adding to its business-development capacity.
“that's the reason why we decided on March -- on February this year to actually do this collaboration with Hangzhou Sciwind Biosciences for the commercialization of ecnoglutide in China.”
Pfizer entered a collaboration with Hangzhou Sciwind Biosciences to commercialize the GLP-1 ecnoglutide in China's large obesity market.
“we're not coming very late into the market because remember, Lilly really introduced their asset in -- at the beginning of last year.”
Pfizer references Lilly as the incumbent in the China/international obesity (GLP-1) market as Pfizer launches ecnoglutide, noting it is not far behind Lilly's entry.
“even after many months of competition from Merck holding share steady at 70%.”
Pfizer says its Prevnar adult pneumococcal vaccine is holding 70% share despite competition from Merck's rival adult pneumococcal vaccine.
“our adjusted gross margins have generally remained in the mid-to-upper 70s when excluding Comirnaty, which is a 50-50 profit split with our partner BioNTech.”
BioNTech is Pfizer's Comirnaty COVID vaccine partner under a 50-50 profit split, which weighs on Pfizer's reported gross margin.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
PFE Pfizer | 5 | +5.4% | |
| ABBV AbbVie | 9 | +12.4% | |
| AMGN Amgen Inc. | 8 | +5.8% | |
| BIIB Biogen | 2 | +1.9% | |
| BMY Bristol Myers Squibb | 4 | +2.6% | |
| GILD Gilead Sciences | 8 | +4.4% | |
| JNJ Johnson & Johnson | 7 | +9.9% | |
| LLY Lilly (Eli) | 10 | +55.5% | |
| MRK Merck & Co., Inc. | 7 | +4.3% |